Shares of Insys Therapeutics Inc. (NASDAQ:INSY) rose 6.4% during trading on Tuesday . The company traded as high as $19.20 and last traded at $18.91, with a volume of 562,859 shares traded. The stock had previously closed at $17.77.

INSY has been the subject of a number of research reports. Janney Montgomery Scott initiated coverage on Insys Therapeutics in a research report on Thursday, April 14th. They set a “buy” rating and a $22.00 price target for the company. Jefferies Group reaffirmed a “buy” rating and set a $22.00 price target (up previously from $17.00) on shares of Insys Therapeutics in a research report on Thursday, August 4th. Zacks Investment Research raised Insys Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Wednesday, June 29th. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a research report on Saturday, April 30th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $28.00 price target on shares of Insys Therapeutics in a research report on Wednesday, July 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $24.67.

The company has a market capitalization of $1.34 billion and a price-to-earnings ratio of 28.27. The firm’s 50-day moving average price is $15.16 and its 200-day moving average price is $15.76.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings data on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by $0.01. During the same quarter in the prior year, the company earned $0.21 earnings per share. The firm earned $67.10 million during the quarter, compared to analyst estimates of $66.90 million. The company’s revenue for the quarter was down 13.6% on a year-over-year basis. Equities research analysts expect that Insys Therapeutics Inc. will post $0.40 earnings per share for the current fiscal year.

In related news, VP Daniel Brennan sold 5,781 shares of the stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $19.16, for a total value of $110,763.96. Following the transaction, the vice president now owns 1 shares of the company’s stock, valued at $19.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Theodore H. Stanley sold 16,000 shares of the stock in a transaction on Monday, June 6th. The shares were sold at an average price of $16.27, for a total value of $260,320.00. Following the completion of the transaction, the director now directly owns 18,000 shares in the company, valued at approximately $292,860. The disclosure for this sale can be found here.

Other institutional investors have bought and sold shares of the company. Globeflex Capital L P raised its position in Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock valued at $1,135,000 after buying an additional 39,600 shares during the period. California State Teachers Retirement System raised its position in Insys Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,625 shares of the specialty pharmaceutical company’s stock valued at $1,249,000 after buying an additional 754 shares during the period. Airain ltd acquired a new position in Insys Therapeutics during the fourth quarter valued at approximately $1,309,000. Bank of Montreal Can raised its position in Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock valued at $1,909,000 after buying an additional 5,733 shares during the period. Finally, California Public Employees Retirement System raised its position in Insys Therapeutics by 178.7% in the fourth quarter. California Public Employees Retirement System now owns 97,000 shares of the specialty pharmaceutical company’s stock valued at $2,777,000 after buying an additional 62,200 shares during the period.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.